Point72 Asset Management
CRBP icon

Point72 Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Point72 Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-51,296
Closed -$482K – 4097
2026
Q1 		$482K Sell
51,296
-23,838
-32% -$201K ﹤0.01% 3132
2025
Q4 		$612K Buy
+75,134
New +$927K ﹤0.01% 3140
2024
Q3 		– Sell
-216,515
Closed -$9.8M – 2040
2024
Q2 		$9.8M Sell
216,515
-485,082
-69% -$20.4M 0.03% 625
2024
Q1 		$27.5M Buy
+701,597
New +$17.3M 0.07% 351
2020
Q3 		– Sell
-50,000
Closed -$12.6M – 949
2020
Q2 		$12.6M Buy
+50,000
New +$10.1M 0.08% 284
2017
Q3 		– Sell
-6,302
Closed -$1.19M – 902
2017
Q2 		$1.19M Buy
+6,302
New +$1.24M 0.01% 713

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Point72 Asset Management's CRBP Position: Q2 2026 in Review

Point72 Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2026, closing a stake of 51,296 shares — an estimated $482K sold.

Point72 Asset Management first reported a position in CRBP in Q2 2017 and held it in 6 quarters. The position peaked at $27.5M in Q1 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Point72 Asset Management reported no remaining Corbus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Point72 Asset Management sold 51,296 Corbus Pharmaceuticals shares in Q2 2026, an estimated $482K.
  • Point72 Asset Management first reported a position in Corbus Pharmaceuticals in Q2 2017 and held it in 6 quarters.
  • Point72 Asset Management's Corbus Pharmaceuticals position peaked at $27.5M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.